Menu

An Obesity-Cancer Link?

Why obese individual are more likely to get cancer could be partly explained by a gene that activates both pathways.

Nov 22, 2011
Edyta Zielinska

FLICKR, JILL A. BROWN

A gene variant found in some 30 percent of type 2 diabetics can inhibit the action of p53—the gatekeeper of the cell cycle and one of the most commonly mutated genes across cancers, according to research from Lund University Diabetes Centre.

The gene TCF normally protects insulin-producing ß-cells from damage due to excess sugar exposure. But a number of diabetics have a variant of this gene that impairs the cell’s ability to secrete insulin, eventually killing the ß-cell, thus leading to diabetes.

In a study published in the journal Human Molecular Genetics, the researchers looked for the molecules that interacted with the TCF variant and noticed that one of them was p53. When they blocked TCF in the cell, the levels of p53 went up, demonstrating a link between the cancer-related gene and TCF.  When TCF isn’t blocked, p53 expression is suppressed, rendering cells much more likely to accumulate mutations during division that could lead to cancer.

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry’s first digital PCR products to receive U.S. Food and Drug Administration (FDA) clearance. Used together, Bio-Rad’s system and kit can precisely and reproducibly monitor molecular response to treatment in patients with chronic myeloid leukemia (CML).
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.